Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00425607 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria
A Phase 2 study of Progeria and Hutchinson-Gilford Syndrome, sponsored by Monica E. Kleinman.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT00425607 is a Phase 2 study of Progeria and Hutchinson-Gilford Syndrome that has completed, run by Monica E. Kleinman. The registered enrollment target is 29 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00425607, a Phase 2 study of Progeria and Hutchinson-Gilford Syndrome, has completed, sponsored by Monica E. Kleinman.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label dose adjusted phase II trial of the oral farnesyltransferase inhibitor (FTI) lonafarnib (SCH66336) for patients with HGPS and progeroid laminopathies.
Conditions Studied
Interventions
- DRUG Lonafarnib
Study Locations (1)
Massachusetts
- Children's Hospital Boston - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00425607
The ClinicalTrials.gov registry entry for NCT00425607 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Monica E. Kleinman, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Progeria appearing as the primary indexed condition, and to 1 intervention - of which Lonafarnib is the first listed.
NCT00425607 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00425607 about?
NCT00425607 is a clinical study titled "Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria". This is an open label dose adjusted phase II trial of the oral farnesyltransferase inhibitor (FTI) lonafarnib (SCH66336) for patients with HGPS and progeroid laminopathies.
What is the current status of trial NCT00425607?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2007-05. Estimated completion is 2009-10.
What conditions does trial NCT00425607 study?
This clinical trial studies the following conditions: Progeria, Hutchinson-Gilford Syndrome.
What interventions are being tested in trial NCT00425607?
The interventions under investigation include: Lonafarnib (DRUG).
Who is sponsoring clinical trial NCT00425607?
This trial is sponsored by Monica E. Kleinman, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00425607 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.